Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion Abstract #1935

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.
Aim(s): To examine the prevalence of patients with pNENs and serotonin secretion.
Materials and methods: From our unit database patients with increased levels of 5HIAA in 24h urine and/or carcinoid syndrome were included.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2909 Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?
Introduction: Serotonin-secreting pancreatic neuroendocrine neoplasms (5-HT-secreting pNENs) are very rare. They are characterised by high urinary 5-hydroxyindole-acetic acid (5-HIAA) levels (or high serum 5-HT levels).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review
Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Marion Feuilly
Authors: Haig J, Kohli M, Pastor L, Feuilly M, ...
#1517 Additional Value for Urinary 5-Hydroxyindoleacetic Acid as Prognostic Marker in Neuroendocrine Tumors?
Introduction: 5-Hydroxyindoleacetic Acid (5-HIAA) is of value for diagnosis of NETs and correlates with severity of carcinoid syndrome. However its value for determining prognosis is uncertain, particularly in combination with other biomarkers
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wouter Zandee
Keywords: prognosis 5-HIAA
#1800 Validation and Comparison between Current Prognostication Systems for Pancreatic Neuroendocrine Neoplasms: Single Institution Experience with 176 Patients
Introduction: Presently, the optimal prognostication system for pancreatic neuroendocrine neoplasms (PNEN) remains unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Assoc Prof Brian Goh
Authors: Goh B, Teo R, Tai D, Allen J, ...
Keywords: PNEN, prognosis